Hannah and I were discussing this drug. Prof Halmagyi here in Sydney said it was worth a try if I was not up for trying Flunarizine which has a rather horrific 19-day half-life! Flunarizine is also associated with causing depression (11 people out of 830 in one clinical trial). These two drugs are both Ca+ channel blockers and both have antihistamine effects. Cinnarizine has a half-life of just 4 hours.
There's more info here:http://home.intekom.com/pharm/janssen/stugeron.html
And here's the result of an open-label clinical trial. Still no doubled-blinded reports unfortunately.Open-Label Trial of Cinnarizine in Migraine ProphylaxisHeadache
Objective —To assess the effectiveness and safety of cinnarizine as a migraine-preventive therapy.
Methods —Sixty patients with more than 2 migraine headache attacks during a 4-week baseline entered the study and received a 25-mg tablet cinnarizine twice daily for the first 3 days and then 3 times daily. They were assessed on weeks 2, 6, 10, and 14. Reduction from baseline in 4-week migraine headache rate was the primary efficacy variable. Reduction in migraine attacks duration and severity was also evaluated.
Results —The mean reduction in 4-week migraine headache rate was 4.6 ± 2.2 from the baseline of 6.2 ± 2.2 after 14 weeks of treatment, which was statistically significant (P < 0.001). Percent reduction in 4-week migraine frequency was 35% after 2 weeks, 74% after 6 weeks, 74% after 10 weeks, and 75% after 14 weeks of treatment. Significant reduction in attack duration (P < 0.001) and severity (P < 0.001) was also noted. No serious adverse events were observed in this series of patient.
Conclusion —Cinnarizine is an efficacious and well-tolerated prophylactic antimigraine medication, which has early onset effectiveness.
I'll post the paper later on. I might try this stuff at some stage if the SSRIs burn out.
EDIT: Here's the full paper. http://www.mvertigo.org/articles/cinnarizine.pdf